Table 2.
| Author | Year | Country | Study design | N | Patient demographics | Cause of injury | Pathogens | NPWT duration (days) | Additional treatment | Final wound closure | Follow up (months) | Qualitya |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Li et al. [31] | 2019 | China | Prospective longitudinal | 18 | 14-57 yr, 67% ♂, no comorbidities | 61% traffic, 39% crush | Monomicrobial | Unknown | Antibiotic bone cement, systemic antibiotics | Skin flap transplant | 29.7 | High 7/9 |
| Yikemu et al. [35] | 2019 | China | Prospective longitudinal | 78 | 44.5 ± 10.5 (23-68) yr, 67% ♂, no comorbidities | 69% traffic, 16% high fall, 10% crush, 5% other | Unknown | Unknown | Ilizarov bone transport technique + antibiotic treatment | Unknown | 18.9 | High 7/9 |
| Izadpanah et al. [32] | 2017 | Germany | Retrospective longitudinal | 106 | 54 yr (SD 19), 73% ♂, comorbidities | Unknown | 20% polymicrobial, 67% monomicrobial (5.6% resistant), 13% unknown | Unknown | Systemic antibiotics | 78% secondary suture/mesh graft, 22% muscle flap | >12 | High 9/9 |
| Deng et al. [33] | 2014 | China | Retrospective longitudinal | 15 | 44.5 (24-68) yr, 60% ♂, comorbidities unknown | Motor vehicle accidents | 93.3% monomicrobial (6.7% resistant), 6.7% polymicrobial | 25.2 (14-56) | Systemic antibiotics | 93.3% granulation tissue, 6.7% skin graft | 22.6 | High 8/9 |
| Kollrack et al. [34] | 2012 | Germany | Prospective longitudinal | 7 | 63.14 ± 4.41 yr, 29% ♂, comorbidities | Unknown | Monomicrobial | 54.43 ± 7.74 | Unknown | Mesh grafting | N/A | High 7/9 |
| Tan et al. [37] | 2011 | China | Retrospective longitudinal case-control | 35 (33) | 43.4 (18-82) yr, 74% ♂, comorbidities unknown | Unknown | Monomicrobial (9.4% resistant) | 9.2 (4-12) | Antibiotic treatment | 47.2% muscle flap, 52.8% secondary closure | 15 | High 9/9 |
| Diefenbeck et al. [36] | 2011 | Germany | Prospective longitudinal | 43 | 50.7 (19-96), comorbidities unknown | Unknown | Monomicrobial (14.3% resistant) | 13.5 (10-16) | Systemic antibiotics | 72.1% secondary closure, 14.0% skin graft, 14.0% muscle flap | 32-51 | High 8/9 |
| Timmers et al. [30] | 2009 | NL | Retrospective longitudinal case-control | 30 (94) | 52 (26-81) yr, 47% ♂, 60% comorbidities | Traumatic | 43.3% polymicrobial, 56.7% monomicrobial | 22.4 (6-60) | Local antiseptic fluid | Unknown | 43-89 | High 9/9 |
aQuality assessment was performed using the Newcastle-Ottawa Quality Assessment Scale (see Table 1).